Center for Scientific Review; Notice of Closed Meetings, 8093 [2018-03702]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 37 / Friday, February 23, 2018 / Notices
• In Paper 2, Respondent falsified
and/or fabricated the record in:
daltland on DSKBBV9HB2PROD with NOTICES
—Figure 2A (top), by reporting results
for the Rescue condition that did not
originate from experimental
observations
—Figure 3C (right), by reporting results
for the Rescue condition that did not
originate from experimental
observations
Dr. Skau entered into a Voluntary
Settlement Agreement and voluntarily
agreed, beginning on January 25, 2018:
(1) To have her research supervised
for a period of three (3) years;
Respondent agreed to ensure that prior
to the submission of an application for
PHS support for a research project on
which Respondent’s participation is
proposed and prior to Respondent’s
participation in any capacity on PHSsupported research, the institution
employing her must submit a plan for
supervision of Respondent’s duties to
ORI for approval; the plan for
supervision must be designed to ensure
the scientific integrity of Respondent’s
research contribution; Respondent
agreed that she will not participate in
any PHS-supported research until a plan
for supervision is submitted and
approved by ORI; Respondent agreed to
maintain responsibility for compliance
with the agreed upon plan for
supervision.
(2) that for a period of three (3) years,
any institution employing her must
submit in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHS
supported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) if no supervisory plan is provided
to ORI, to provide certification to ORI
on annual basis that she has not engaged
in, applied for, or had her name
included on any application, proposal,
or other request for PHS funds without
prior notification to ORI;
(4) to exclude herself voluntarily from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of three (3) years;
and
(5) to the correction or retraction of:
• Cell 167(6):1571–1585, 2016
VerDate Sep<11>2014
20:03 Feb 22, 2018
Jkt 244001
• Proceedings of the National Academy
of Sciences 112(19):E2447–E2456,
2015
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018–03766 Filed 2–22–18; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cancer Drug Development and
Therapeutics.
Date: March 19–20, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Lilia Topol, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892 301–451–
0131, ltopol@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Disease
Prevention and Management, Risk Reduction
and Health Behavior Change.
Date: March 19–20, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Westin Grand, 2350 M Street NW,
Washington, DC 20037.
Contact Person: Michael John McQuestion,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
Bethesda, MD 20892, 301–480–1276,
mike.mcquestion@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR17–316:
Biomedical Technology Research Resource
(P41).
Date: March 19, 2018.
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
8093
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Mark Caprara, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5156,
MSC 7844, Bethesda, MD 20892, 301–435–
1042, capraramg@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Bacterial Pathogenesis.
Date: March 19, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Richard G Kostriken,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192,
MSC 7808, Bethesda, MD 20892, 240–519–
7808, kostrikr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business Hematology.
Date: March 19–20, 2018.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Bukhtiar H. Shah, DVM,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4120,
MSC 7802, Bethesda, MD 20892, 301–806–
7314, shahb@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 16, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–03702 Filed 2–22–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Center for Scientific
Review Advisory Council.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
E:\FR\FM\23FEN1.SGM
23FEN1
]]>Agencies
[Federal Register Volume 83, Number 37 (Friday, February 23, 2018)]
[Notices]
[Page 8093]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-03702]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Cancer Drug Development and Therapeutics.
Date: March 19-20, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW, Washington, DC 20015.
Contact Person: Lilia Topol, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD 20892 301-451-
0131, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Disease Prevention and Management, Risk Reduction and Health
Behavior Change.
Date: March 19-20, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Westin Grand, 2350 M Street NW, Washington, DC 20037.
Contact Person: Michael John McQuestion, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114, Bethesda, MD 20892, 301-
480-1276, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR17-316: Biomedical Technology Research Resource (P41).
Date: March 19, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW, Washington, DC 20015.
Contact Person: Mark Caprara, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5156, MSC 7844, Bethesda, MD 20892, 301-435-
1042, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Topics in Bacterial Pathogenesis.
Date: March 19, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda,
MD 20814.
Contact Person: Richard G Kostriken, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192, MSC 7808, Bethesda, MD
20892, 240-519-7808, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business Hematology.
Date: March 19-20, 2018.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bukhtiar H. Shah, DVM, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4120, MSC 7802, Bethesda, MD
20892, 301-806-7314, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: February 16, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-03702 Filed 2-22-18; 8:45 am]
BILLING CODE 4140-01-P
